The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study

På svenska

Author

  • Jean Henrik Braconier
  • Otto Paulsen
  • Katarina Engman
  • Anders Widell

Summary, in English

16 patients with chronic hepatitis C virus (HCV) infection were treated with a combination of interferon-alpha and ribavirin for 24 weeks in an open study. One patient declined further treatment due to depression after week 16 and did not complete further follow-up. A moderate decline was observed in hemoglobin and an increase in bilirubin level both reversible after discontinuing the treatment. 24 weeks after treatment cessation 9/15 (60%) evaluable patients had complete clearance of HCV-RNA as measured with PCR. HCV genotype did not seem to be correlated with response, but patients with sustained response to treatment had a significantly reduced number of HCV RNA copies/ml serum at treatment start compared with the other patients. These findings support the promising results of this combination therapy noted in other pilot studies.

Publishing year

1995

Language

English

Pages

325-329

Publication/Series

Scandinavian Journal of Infectious Diseases

Volume

27

Issue

4

Document type

Journal article

Publisher

Informa Healthcare

Topic

  • Infectious Medicine

Status

Published

Research group

  • Clinical Microbiology, Malmö

ISBN/ISSN/Other

  • ISSN: 1651-1980